Standard BioTools Inc. (LAB) stock

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value

$0.71+0.06 (+8.60%)

Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –

Standard BioTools pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Standard BioTools's pe ratio was 2.9× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.9×	–

Parsed from the XBRL in Standard BioTools's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LAB.

Revenue growth-4.8% · median 39.9%

Operating margin-112.8% · median -132.2%

Net margin100.4% · median -161.5%

Advertisement
300 × 250

See a number that looks wrong?